Literature DB >> 15876809

Intravenous iron therapy as a possible risk factor for atherosclerosis in end-stage renal disease.

Kadriye Altok Reis1, Galip Guz, Hakan Ozdemir, Yasemin Erten, Veli Atalay, Zerrin Bicik, Zubeyde Nur Ozkurt, Musa Bali, Sukru Sindel.   

Abstract

Atherosclerosis is a disease of the arterial wall, with increasing wall thickness representing an early event in the progression of the disease. It has been suggested that iron overload, as assessed by increased serum ferritin concentration, may be a risk factor for atherosclerosis. The aim of this study was to investigate the relationship between the influence of intravenous (IV) iron therapy and ferritin levels and carotid intima media thickness (C-IMT) in dialysis patients. Sixty patients (51 +/- 14) years were divided into two groups according to their IMT obtained by ultrasound; group I (high risk) and group II (low risk). The parameters assessed were serum creatinine, urea, calcium, phosphorus, hemoglobin, albumin, uric acid, iron, ferritin, and lipid levels. Thirty-eight patients (88%) in group I and 5 patients (12%) in group II received IV iron therapy while 5 patients (29%) in group I and 12 patients (71%) in group II (P < 0.001) did not receive IV iron therapy. Ferritin levels were higher in group I than in group II (581 +/- 303 and 306 +/- 224) (P < 0.001). C-IMT measurements correlated with serum ferritin and with the intravenous iron dose received during the 24 months preceding the study (r = 0.315, P = 0.015; r = 0.471, P = 0.001). The findings indicate that IV iron therapy and elevated serum ferritin levels may cause an increase in the incidence of atherosclerosis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15876809     DOI: 10.1536/ihj.46.255

Source DB:  PubMed          Journal:  Int Heart J        ISSN: 1349-2365            Impact factor:   1.862


  21 in total

1.  Enarodustat, Conversion and Maintenance Therapy for Anemia in Hemodialysis Patients: A Randomized, Placebo-Controlled Phase 2b Trial Followed by Long-Term Trial.

Authors:  Tadao Akizawa; Masaomi Nangaku; Takuhiro Yamaguchi; Masanobu Arai; Ryosuke Koretomo; Kazuo Maeda; Yuya Miyazawa; Hideki Hirakata
Journal:  Nephron       Date:  2019-05-22       Impact factor: 2.847

2.  Iron sucrose promotes endothelial injury and dysfunction and monocyte adhesion/infiltration.

Authors:  Vaijinath S Kamanna; Shobha H Ganji; Stanislav Shelkovnikov; Keith Norris; Nosratola D Vaziri
Journal:  Am J Nephrol       Date:  2011-12-29       Impact factor: 3.754

Review 3.  Iron overdose: a contributor to adverse outcomes in randomized trials of anemia correction in CKD.

Authors:  Peter Van Buren; Ruben L Velez; Nosratola D Vaziri; Xin J Zhou
Journal:  Int Urol Nephrol       Date:  2011-07-10       Impact factor: 2.370

Review 4.  Cardiovascular co-morbidity in chronic kidney disease: Current knowledge and future research needs.

Authors:  Hudaifa Alani; Asad Tamimi; Nihad Tamimi
Journal:  World J Nephrol       Date:  2014-11-06

Review 5.  Safety of intravenous iron in hemodialysis patients.

Authors:  Xiaojuan Li; Abhijit V Kshirsagar; M Alan Brookhart
Journal:  Hemodial Int       Date:  2017-04-03       Impact factor: 1.812

6.  Cumulative iron dose and resistance to erythropoietin.

Authors:  A Rosati; C Tetta; J I Merello; I Palomares; R Perez-Garcia; F Maduell; B Canaud; P Aljama Garcia
Journal:  J Nephrol       Date:  2014-08-05       Impact factor: 3.902

7.  Parenteral iron use: possible contribution to exceeding target hemoglobin in hemodialysis patients.

Authors:  Hassan N Ibrahim; Robert N Foley; Rui Zhang; David T Gilbertson; Allan J Collins
Journal:  Clin J Am Soc Nephrol       Date:  2009-02-11       Impact factor: 8.237

8.  Intravenous iron exposure and mortality in patients on hemodialysis.

Authors:  Dana C Miskulin; Navdeep Tangri; Karen Bandeen-Roche; Jing Zhou; Aidan McDermott; Klemens B Meyer; Patti L Ephraim; Wieneke M Michels; Bernard G Jaar; Deidra C Crews; Julia J Scialla; Stephen M Sozio; Tariq Shafi; Albert W Wu; Courtney Cook; L Ebony Boulware
Journal:  Clin J Am Soc Nephrol       Date:  2014-10-15       Impact factor: 8.237

Review 9.  Iron dosing in kidney disease: inconsistency of evidence and clinical practice.

Authors:  Adam E Gaweda; Yelena Z Ginzburg; Yossi Chait; Michael J Germain; George R Aronoff; Eliezer Rachmilewitz
Journal:  Nephrol Dial Transplant       Date:  2014-05-12       Impact factor: 5.992

Review 10.  Hydroxyl radical and its scavengers in health and disease.

Authors:  Boguslaw Lipinski
Journal:  Oxid Med Cell Longev       Date:  2011-07-17       Impact factor: 6.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.